Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase
O Dreazen, M Berman, RP Gale - 1988 - ashpublications.org
Median duration of the chronic phase of chronic myelogenous leukemia (CML) is 3 years;
less than 20% of patients have a chronic phase greater than 7 years. It is unknown whether …
less than 20% of patients have a chronic phase greater than 7 years. It is unknown whether …
Persistence of bcr-abl gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase
DS SNYDER, JJ ROSSI, JLIN WANG… - …, 1991 - journals.lww.com
The bcr-abl RNA transcript is the molecular counterpart of the Philadelphia chromosome
and is detectable by an extremely sensitive polymerase chain reaction assay in most …
and is detectable by an extremely sensitive polymerase chain reaction assay in most …
PCR‐monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR‐ABL‐positive acute lymphoblastic …
G Mitterbauer, M Födinger, R Scherrer… - British journal of …, 1995 - Wiley Online Library
We report the results of consecutive tests in nine BCR‐ABL‐positive ALL patients by one‐
step and two‐step (nested primer) reverse transcriptase‐polymerase chain reaction (RT …
step and two‐step (nested primer) reverse transcriptase‐polymerase chain reaction (RT …
Detection of minimal residual disease in acute myeloid leukaemia: methodologies, clinical and biological significance.
L Yin, A John, K Tobal - British journal of haematology, 1999 - search.ebscohost.com
Provides information on methodologies in detecting minimal residual disease (MRD) in
acute myeloid leukemia. Processes involved in florescence in situ hybridization; Nucleic …
acute myeloid leukemia. Processes involved in florescence in situ hybridization; Nucleic …
Minimal residual disease in chronic myeloid leukemia
B Löwenberg - New England Journal of Medicine, 2003 - Mass Medical Soc
For many years hematologists have used the microscope to identify a complete remission of
leukemia after treatment with chemotherapy. In a hematologic complete remission, we know …
leukemia after treatment with chemotherapy. In a hematologic complete remission, we know …
Impact of RNA Stabilization on Minimal Residual Disease Assessment in Chronic Myeloid Leukemia.
I Thörn, U Olsson-Strömberg, C Ohlsen… - 2005 - ashpublications.org
Background and objective: Accurate quantification of BCR-ABL mRNA is of critical
importance for managing chronic myeloid leukemia (CML) patients receiving Imatinib …
importance for managing chronic myeloid leukemia (CML) patients receiving Imatinib …
Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.
N Frenoy, A Chabli, O Sol, E Goldschmit… - Leukemia, 1994 - europepmc.org
Nested PCR (NPCR), a two-step procedure in which the products of a first PCR
using'outer'primers are reamplified using'inner primers', has been successfully used to test …
using'outer'primers are reamplified using'inner primers', has been successfully used to test …
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy
JQ Guo, JY Lian, YM Xian, MS Lee, AB Deisseroth… - 1994 - ashpublications.org
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder associated with the
Philadelphia chromosome (Ph1) in more than 95% of these patients. The Ph1 and the …
Philadelphia chromosome (Ph1) in more than 95% of these patients. The Ph1 and the …
Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance
F Ravandi, J Cortes, M Albitar… - British journal of …, 1999 - Wiley Online Library
We investigated the significance of p185BCR/ABL expression in patients with chronic
myelogenous leukaemia (CML) in relation to disease features, therapy and outcome …
myelogenous leukaemia (CML) in relation to disease features, therapy and outcome …
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia.
A Grossman, RT Silver, TP Szatroswki, A Gutfriend… - Leukemia, 1991 - europepmc.org
The characteristic genetic exchange in chronic myeloid leukemia (CML) is the fusion of the
ABL proto-oncogene and a specific part of the BCR or phl gene. Detection of this exchange …
ABL proto-oncogene and a specific part of the BCR or phl gene. Detection of this exchange …